DTaP-IPV Vaccines

<table>
<thead>
<tr>
<th>DTaP-IPV Vaccines</th>
<th>Recommended Age</th>
<th>Booster Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinrix™ (GlaxoSmithKline)</td>
<td>4 – 6 years (Booster dose only)</td>
<td>0.5 mL at least 6 months after the 4th dose of DTaP and 6 months after the previous dose of IPV</td>
</tr>
<tr>
<td>Quadracel™ (Sanofi Pasteur)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DTaP-IPV Vaccine Recommendations**

**General Recommendations:**
- Both DTaP-IPV vaccines **are not** approved for the primary series of DTaP and/or IPV in children 4 through 6 years of age.
- A single dose of Kinrix is licensed only for the fifth dose in the DTaP series and fourth dose in the IPV series in children whose DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.
- A single dose of Quadracel is licensed for use as the fifth dose of DTaP and fourth or fifth dose of IPV in children who received DTaP-IPV-Hib (Pentacel) and/or DTaP (Daptacel) vaccine for the first 4 doses.
- Either vaccine may be used when any component of the combination is indicated, and if the other components are not contraindicated for the booster dose at 4-6 years of age.

**Administration:**
- Whenever possible, it is recommended that the same DTaP vaccine should be used for all doses in the series.
- If a provider does not know or have available the DTaP vaccine product previously administered, vaccine administration should not be deferred and either DTaP-IPV vaccine may be administered.
- If either DTaP vaccine is inadvertently administered before age 4 years (i.e. at 2 months, 4 months, 6 months) for an earlier dose of the DTaP and/or IPV series and if minimum interval requirements have been met, the dose may be counted as valid for the DTaP and/or IPV series and does not need to be repeated.
- Note that the final dose in the IPV series must be administered at age ≥4 years regardless of the number of previous doses, and with a minimum interval of 6 months from the previous dose. Therefore, a dose of DTaP-IPV vaccine administered before the fourth birthday can’t be counted as a valid final dose of IPV.
- **DTaP:** a fifth dose of DTaP-containing vaccine is not needed if the fourth dose was given on or after the fourth birthday.
- **IPV:** A fourth dose of IPV-containing vaccine is not needed if the third IPV dose was given on or after the fourth birthday and was given at least 6 months after the previous dose.

**Adverse Reactions**
- Injection site: pain, redness, swelling, increase in arm circumference.
- Systemic: drowsiness, fever, loss of appetite.

**Contraindications**
- Hypersensitivity (anaphylaxis reaction after a previous dose of any diphtheria toxoid, tetanus toxoid, pertussis or poliovirus-containing vaccine).
- Encephalopathy (coma, decreased level of consciousness, prolonged seizures).
- Progressive neurologic disorder (infantile spasms, uncontrolled epilepsy, progressive encephalopathy).

**Precautions**
- Guillain-Barre Syndrome occurring within 6 weeks of receipt of a prior vaccine containing tetanus toxoid.
- Adverse events following prior pertussis vaccination.
- Children at risk for seizures.
- Temperature of 105°F within 48 hours not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hypo responsiveness episode) within 48 hours.
- Seizures with or without fever occurring within 3 days.